BioAtla Granted Continued Nasdaq Listing with Conditions

An update from BioAtla ( (BCAB) ) is now available.

BioAtla, Inc. faced a delisting determination from Nasdaq on August 6, 2025, due to non-compliance with the Minimum Bid Price and Minimum Stockholders’ Equity Requirements. After presenting a Compliance Plan to Nasdaq, which included potential strategic partnerships and clinical developments, the company was granted continued listing on September 16, 2025, with conditions to meet specific compliance deadlines. BioAtla submitted an application to transfer to The Nasdaq Capital Market on September 18, 2025, and aims to meet the equity and bid price requirements by the end of 2025 and early 2026, respectively.

The most recent analyst rating on (BCAB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.

Spark’s Take on BCAB Stock

According to Spark, TipRanks’ AI Analyst, BCAB is a Underperform.

BioAtla’s stock faces significant challenges, primarily due to its financial position, characterized by a lack of revenue and high cash burn. Despite promising clinical progress and strategic efforts to manage cash, the company’s valuation and technical indicators reflect a bearish outlook. The overall score reflects these substantial risks, with some potential upside from clinical developments.

To see Spark’s full report on BCAB stock, click here.

More about BioAtla

BioAtla, Inc. operates in the biotechnology industry, focusing on developing novel therapeutics for the treatment of cancer. The company is known for its proprietary Conditionally Active Biologic (CAB) technology, which aims to create safer and more effective cancer treatments.

Average Trading Volume: 779,840

Technical Sentiment Signal: Sell

Current Market Cap: $36.52M

For detailed information about BCAB stock, go to TipRanks’ Stock Analysis page.